NCT03897946View on ClinicalTrials.gov

Evaluating Immunogenicity of a Birth Dose of HBV Vaccine in the DRC

PHASE4CompletedINTERVENTIONAL
Enrollment

569

Participants

Timeline

Start Date

August 20, 2019

Primary Completion Date

February 5, 2021

Study Completion Date

February 5, 2021

Conditions
Hepatitis B
Interventions
BIOLOGICAL

Birth dose hepatitis B vaccine

Groups A and C will receive a birth dose of hepatitis B vaccine within 24 hours of life.

Trial Locations (1)

Unknown

Binza and Kingasani Maternity Centers, Kinshasa

All Listed Sponsors
collaborator

The American Society of Tropical Medicine and Hygiene

OTHER

collaborator

Burroughs Wellcome

INDUSTRY

lead

University of North Carolina, Chapel Hill

OTHER

NCT03897946 - Evaluating Immunogenicity of a Birth Dose of HBV Vaccine in the DRC | Biotech Hunter | Biotech Hunter